Nephrotic syndrome with pegylated interferon alfa 2a and ribavirin for a patient with chronic hepatitis C.
Sood
Ajit
A
Midha
Vandana
V
Sandhu
Jaswinder S
JS
Sood
Neena
N
Kaur
Amarjit
A
Mittal
Rasham
R
Puri
Sandeep
S
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D004232:Diuretics / Q000627:therapeutic use; D005923:Glomerulosclerosis, Focal Segmental / Q000139:chemically induced* / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*
D000998:Antiviral Agents; D004232:Diuretics; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a
Int Urol Nephrol. 2008;40(2):539-41
17987400
Am J Kidney Dis. 2003 Oct;42(4):631-57
14520615
Am J Kidney Dis. 1998 Jan;31(1):121-6
9428462
Liver Int. 2006 Dec;26(10):1294-7
17105597
J Clin Oncol. 1986 Feb;4(2):234-43
2418169
Cancer. 1986 Apr 15;57(8 Suppl):1709-15
3948143
Am J Kidney Dis. 1996 Dec;28(6):888-92
8957041
Dig Dis Sci. 2001 Mar;46(3):530-5
11318527
J Clin Gastroenterol. 2002 Jul;35(1):89-92
12080234
Am J Clin Oncol. 2003 Jun;26(3):262-4
12796597